Clinical Trials
Gene Therapy Trial for Advanced PD Now Recruiting
A Phase 1/2 study at UCSF is testing AAV2-GDNF — a gene therapy that delivers the GDNF protein directly into the brain via a surgical procedure. The goal is to promote the survival of dopamine-producing neurons that are lost in Parkinson's. The trial targets patients ages 45–70 with advanced disease who have developed motor complications from long-term levodopa use. Patients must be on stable medication for at least 4 weeks with no prior brain surgery or gene therapy.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: Patients must be on stable medication for at least 4 weeks with no prior brain surgery or gene therapy.
Limit: An ongoing trial does not prove effectiveness or mean the treatment is available.
Source: clinicaltrials.ucsf.eduDigital Tremor Tracking Study Enrolling Patients and Controls
A prospective study at UCSF is using a smartphone app to objectively measure tremor frequency, amplitude, and severity during daily activities. The goal is to replace subjective patient diaries with continuous sensor data for more accurate symptom tracking. Researchers are enrolling patients with diagnosed Parkinson's and age-matched healthy controls. Participants complete motor tasks at home using the app over a 90-day period.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: Participants complete motor tasks at home using the app over a 90-day period.
Limit: A promising signal is not yet a validated diagnostic test and cannot guide treatment by itself.
Source: clinicaltrials.ucsf.eduAI-Powered DBS Personalization Trial at UCSF
The first AI-designed Parkinson's trial is using machine learning to predict which patients benefit most from adaptive deep brain stimulation (aDBS). The system analyzes brain imaging and motor data to personalize electrode placement and stimulation parameters in real time. The trial is recruiting adults with diagnosed Parkinson's who are already eligible for or have undergone DBS surgery.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: The trial is recruiting adults with diagnosed Parkinson's who are already eligible for or have undergone DBS surgery.
Limit: An ongoing trial does not prove effectiveness or mean the treatment is available.
Source: clinicaltrials.ucsf.edu
Breakthrough Treatments
Physical Therapy Registry Shows Long-Term Benefit
A landmark analysis of the largest Parkinson's registry found that patients in formal, consistent physical therapy programs maintained significantly better motor scores (UPDRS-III) and quality of life measures after 12 months compared to those exercising independently. The data strongly support early, ongoing physical therapy referral as a standard of care — sporadic participation showed minimal benefit.
Research studyLevel: Not stated in reportDesign not statedWhat the study tells us: The data strongly support early, ongoing physical therapy referral as a standard of care — sporadic participation showed minimal benefit.
Limit: Without randomization, an association may reflect other differences rather than the intervention causing the result.
Source: ucsf.eduNew Theory on How Alpha-Synuclein Spreads in the Brain
UCSF scientists published a new mechanistic framework explaining how alpha-synuclein — the misfolded protein that accumulates in Parkinson's brains — propagates from cell to cell via a "templating loop." This new pathway explains disease progression patterns that earlier hypotheses couldn't account for, and identifies targets distinct from existing antibody drugs. Pharmaceutical companies are now using this framework to screen new candidate therapeutics.
Research studyLevel: Not stated in reportDesign not statedWhat the study tells us: UCSF scientists published a new mechanistic framework explaining how alpha-synuclein — the misfolded protein that accumulates in Parkinson's brains — propagates from cell to cell via a "templating loop." This new pathway explains disease progression patterns that earlier hypotheses couldn't account for, and identifies targets distinct from existing antibody drugs.
Limit: Results from cells or animals may not reproduce in people.
Source: ucsf.eduGLP-1 Receptor Agonists Show Unexpected Neuroprotective Signal
A large retrospective analysis of patients with both Type 2 diabetes and Parkinson's found that those taking GLP-1 receptor agonists (like semaglutide) showed measurably slower motor progression compared to matched controls. While these drugs are not approved for Parkinson's, the signal is strong enough to justify dedicated randomized trials. This adds to a growing body of evidence that metabolic pathways influence neurodegeneration.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: This adds to a growing body of evidence that metabolic pathways influence neurodegeneration.
Limit: Results from cells or animals may not reproduce in people.
Source: jamanetwork.com
Lifestyle Interventions
Argentine Tango Beats Standard PT for Balance
A 2025 randomized controlled trial found that 12 weeks of Argentine tango classes outperformed standard physical therapy for improving dynamic balance, functional mobility, and quality of life in Parkinson's patients. Researchers credit the complex balance demands of dancing combined with musical rhythm cues, which activate additional neural circuits beyond what's used in conventional exercise. Many cities now offer Parkinson's-specific dance programs.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: Many cities now offer Parkinson's-specific dance programs.
Limit: The report does not provide enough context to turn this headline into medical advice.
Source: pubmed.ncbi.nlm.nih.govHigh-Intensity Interval Training Confirmed Safe for Early PD
A 2025 study confirmed that supervised high-intensity interval training is safe for early-stage Parkinson's patients with cardiologist clearance. HIIT outperformed moderate continuous exercise for improving VO2 max, and secondary benefits included improved mood and cognitive processing speed. Authors recommend supervised起步 before independent home exercise programs.
Research studyLevel: Not stated in reportDesign not statedWhat the study tells us: Authors recommend supervised起步 before independent home exercise programs.
Limit: Results from cells or animals may not reproduce in people.
Source: pubmed.ncbi.nlm.nih.govBlue Zone Longevity Framework Adapted for Parkinson's
Longitudinal data from "Blue Zones" — regions with unusually high rates of longevity and low Parkinson's prevalence — identified five shared habits: plant-based whole foods, natural movement throughout the day, strong social purpose, quality sleep, and stress-reduction practices. A practical "EAT. MOVE. SLEEP. PROTECT. REPEAT." framework is being piloted in a community PD support program with promising early results.
Research studyLevel: Not stated in reportDesign not statedWhat the study tells us: REPEAT." framework is being piloted in a community PD support program with promising early results.
Limit: Results from cells or animals may not reproduce in people.
Source: pubmed.ncbi.nlm.nih.gov
Emerging Research
Wrist Sensors Detect Parkinson's Years Before Diagnosis
A prospective study using wrist-worn accelerometers found that subtle motor abnormalities — bradykinesia, micrographia, micro-level gait changes — detectable years before clinical Parkinson's diagnosis accurately predicted later disease severity in 80% of cases. This raises the possibility of disease-modifying interventions before significant neuron loss has occurred.
Research studyLevel: Not stated in reportDesign not statedWhat the study tells us: This raises the possibility of disease-modifying interventions before significant neuron loss has occurred.
Limit: A promising signal is not yet a validated diagnostic test and cannot guide treatment by itself.
Source: nature.comBlood Test Identifies 27-Gene Signature in Early PD
RNA sequencing of patient blood samples has identified a 27-gene expression signature that distinguishes early-stage Parkinson's patients from controls with high sensitivity and specificity. The signature correlates with clinical severity scores and is being developed as a biomarker to enrich clinical trial enrollment with truly early-stage participants — a major bottleneck in PD drug development.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: The signature correlates with clinical severity scores and is being developed as a biomarker to enrich clinical trial enrollment with truly early-stage participants — a major bottleneck in PD drug development.
Limit: A promising signal is not yet a validated diagnostic test and cannot guide treatment by itself.
Source: pubmed.ncbi.nlm.nih.govGut Microbiome Differences Found Across All PD Stages
A comprehensive microbiome analysis of stool samples from over 500 Parkinson's patients found consistent depletion of short-chain fatty acid-producing bacteria regardless of diet, medication, or disease duration. This strengthens the gut-brain axis hypothesis and suggests microbiome modulation — through diet or targeted probiotics — as a potential disease-modifying strategy, though controlled human trials are still needed. Generated daily from public research databases. For informational purposes only — not medical advice.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: This strengthens the gut-brain axis hypothesis and suggests microbiome modulation — through diet or targeted probiotics — as a potential disease-modifying strategy, though controlled human trials are still needed.
Limit: Without randomization, an association may reflect other differences rather than the intervention causing the result.
Source: pubmed.ncbi.nlm.nih.gov
This report is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.